Movymia (Teriparatide)

Teriparatide binds to the PTH1 receptor on bone‑forming cells (osteoblasts), activating signaling pathways that increase osteoblast activity and bone matrix production. This anabolic effect leads to greater bone mineral density and stronger skeletal structure.

The specific dose and administration schedule of Movymia are determined by the prescribing physician based on the patient’s clinical condition, weight, and treatment goals. Patients should follow the prescriber’s instructions and not adjust the dose on their own.

Safety of teriparatide in pregnancy and lactation has not been established. It should only be used if the potential benefit justifies the potential risk to the fetus or infant, and this decision must be made by a qualified healthcare professional.

To place an order, submit an enquiry on the product page at gnhindia.com with the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain handling if needed) and necessary import documentation.

Unlike anti‑resorptive agents such as bisphosphonates, teriparatide is an anabolic therapy that actively builds new bone. It is typically reserved for patients with severe osteoporosis or those who have not responded adequately to other treatments, offering a different mechanism of action that can improve bone density more rapidly.

Movymia should be stored at 2‑8 °C (refrigerated). Keep the product in its original packaging, protect it from light, and do not freeze or shake the vial. Maintaining the cold chain is essential to preserve drug stability and efficacy.

Movymia is given as a subcutaneous injection, typically into the thigh or abdomen. The injection is performed by a trained healthcare professional or by the patient after proper instruction. The injection site should be rotated to minimize local reactions.

The most serious risks include the rare development of osteosarcoma, severe hypercalcemia, and serious allergic reactions such as anaphylaxis. Patients should be monitored regularly for signs of these conditions, and any concerning symptoms should be reported to a healthcare provider promptly.

Movymia is contraindicated in individuals with a history of osteosarcoma, unexplained bone lesions, or active Paget disease of bone. It should also be avoided in patients with severe hypercalcemia or those who are pregnant or breastfeeding unless the prescriber determines that the benefits outweigh the risks.